Arcutis Biotherapeutics (ARQT) Cash from Operations (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Cash from Operations of 2239000.0 for Q1 2026, up 107.37% year-over-year from 1079712.69 in Q1 2025, and down 91.45% quarter-over-quarter from 26185000.0 in Q4 2025.
Powered by 
Analysis
Arcutis Biotherapeutics (ARQT) Cash from Operations (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Cash from Operations history runs 8 years deep, the most recent figure standing at 2239000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 107.37% year-over-year to 2239000.0; the TTM figure through Mar 2026 stood at 26994000.0 (up 124.33% YoY), while the FY2025 annual figure was 5625000.0, up 94.98% from the prior year.
- Cash from Operations for Q1 2026 stood at 2239000.0, down from 26185000.0 in the prior quarter.
- The five-year high for Cash from Operations was 26185000.0 in Q4 2025, with the low at 80344000.0 in Q1 2023.
- The 5-year median for Cash from Operations is 43984000.0 (2023), against an average of 36489176.47.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations tumbled 72.98% in 2022, then surged 3600.67% in 2025.
- Arcutis Biotherapeutics' Cash from Operations stood at 71065000.0 in 2022, then advanced by 20.86% to 56244000.0 in 2023, then soared by 98.67% to 748000.0 in 2024, then soared by 3600.67% to 26185000.0 in 2025, then sank by 91.45% to 2239000.0 in 2026.
- Business Quant data shows ARQT's Cash from Operations at 2239000.0 in Q1 2026, 26185000.0 in Q4 2025, and 1754000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Arcutis Biotherapeutics | 3.12 Bn | 2.88 Bn | 118.92 Mn | 12.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.64 Mn |
| Mar 31, 2026 | 2.24 Mn |
| Dec 31, 2025 | 26.19 Mn |
| Sep 30, 2025 | -1.75 Mn |
| Jun 30, 2025 | 324,000.00 |
| Mar 31, 2025 | -30.38 Mn |
| Dec 31, 2024 | -748,000.00 |
| Sep 30, 2024 | -34.69 Mn |
| Jun 30, 2024 | -45.12 Mn |
| Mar 31, 2024 | -31.60 Mn |
| Dec 31, 2023 | -56.24 Mn |
| Sep 30, 2023 | -43.98 Mn |
| Jun 30, 2023 | -66.49 Mn |
| Mar 31, 2023 | -80.34 Mn |
| Dec 31, 2022 | -71.07 Mn |
| Sep 30, 2022 | -67.70 Mn |
| Jun 30, 2022 | -61.98 Mn |
| Mar 31, 2022 | -56.98 Mn |
| Dec 31, 2021 | -51.71 Mn |
| Sep 30, 2021 | -40.88 Mn |